| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -70 | -11,633 | -1,280 | -3,012 | 2,939 |
| Net Income Growth | +99.40% | -808.80% | +57.50% | -202.49% | +122.15% |
Psyence Group Inc (PSYG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Psyence Group Inc is a life science biotechnology company focused on the research, cultivation, and production of psychedelics and nature-based compounds to treat psychological trauma in the context of palliative care and support of mental wellness. It is involved in cultivating and exporting psilocybin mushrooms to the legal medical and research markets; developing drugs in the field of palliative care; and offering a range of non-psilocybin containing functional mushroom nutraceutical products called Goodmind, designed to enhance mental capacity and the body's ability to adapt to stress. The group operates in two segments: clinical trial activities and non-clinical trial activities. Geographically, it has a presence in Canada, the USA, Southern Africa, and the British Virgin Islands.
Fiscal Year End Date: 03/31